ABMD


Zack’s Bull of the Day: ABIOMED

ABIOMED (NASDAQ:ABMD) is a Zacks Rank #1 (Strong Buy), and as such, we know that earnings estimates are moving higher. The company is …

William Blair Maintains Outperform On Abiomed Following F3Q Update

William Blair analyst Ben Andrew maintained an Outperform rating on Abiomed (NASDAQ:ABMD), following the release of the company’sĀ fiscal third-quarter results that topped Street …

William Blair Maintains Outperform On Abiomed Following Clinical Trial Results

In a research report issued today, William Blair analyst Matthew O’BrienĀ maintained an Outperform rating on Abiomed (NASDAQ:ABMD), following the company’s clinical trial results …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts